Back

Genflow Biosciences says SLAB clinical trial met primary endpoint

Verifying
  • Genflow Biosciences PLC announced that the SLAB clinical trial met its primary endpoint.
  • The announcement provides no numerical results or endpoint data.
  • The supplied material contains no further details about timing or next steps.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.